SenesTech, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 14, 2019 and accepted by EDGAR at Aug 14, 2019, 09:16 ET.
Management's discussion and analysis
As filed, 42,503 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As used in this Quarterly Report on Form 10-Q, “SenesTech,” the “Company,” “we,” “us,” or “our” refer to SenesTech, Inc., a Delaware corporation.
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our condensed consolidated financial statements and related notes. Some statements and information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, notes to our condensed consolidated financial statements and elsewhere in this report are not historical facts but are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, readers can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology, which when used are meant to signify the statement as forward-looking. These forward-looking statements include, but are not limited to, our expectations regarding new accounting standards on our financial results, our expectations regarding our critical accounting policies; our expectations regarding our current operating plan, including operating expenses, product sales and revenue expectations, profitability and cash flows, anticipated revenue and sales of our equity securities, our beliefs regarding the use of stock-based awards as a compensation tool, our beliefs regarding certain tax positions, our beliefs regarding our revenue targets and the sufficiency of our liquidity and capital resources, our beliefs regarding ongoing litigation, our expectations regarding our significant employees, our expectations regarding commercialization of ContraPest and product development of our other product candidates, our expectations regarding our sales channel, including distributors, our expectations regarding regulatory approval of our products or product candidates, the continued listing of our common stock on The Nasdaq Capital Market, statements about our plans, objectives, expectations and intentions and other statements that are not historical facts. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our own, or our industry’s actual results, to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Item 1A of Part II of our Annual Report on Form 10-K, as amended by Form 10-K/A, for the year ended December 31, 2018, both filed with the SEC on March 29, 2019 (collectively, the “2018 Annual Report”), entitled “Risk Factors,” and those contained from time to time in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Overview
Since our inception, we have sustained significant operating losses in the course of our research and development activities and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to prepare and launch commercialization of our first product, ContraPest. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock.
We have also raised capital through debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.
Through June 30, 2019, we had received net proceeds of $63.6 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.4 million in net product sales. At June 30, 2019, we had an accumulated deficit of $90.5 million and cash and cash equivalents of $2.6 million.
We have incurred significant operating losses every year since our inception. Our net losses were $2.3 million and $4.7 million for the three and six months ended June 30, 2019 and $4.1 million and $6.8 million for the three and six months ended June 30, 2018, respectively. We expect to continue to incur significant expenses and generate operating losses for at least the next 12 months.
We have historically utilized, and intend to continue to utilize, various forms of stock-based awards in order to hire, retain and motivate talented employees, consultants and directors and encourage them to devote their best efforts to our business and financial success. In addition, we believe that our ability to grant stock-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders.
As a result, a significant portion of our operating expenses includes stock-based compensation expense. Stock-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. Specifically, our stock-based compensation expense for the three and six months ended June 30, 2019 was $219,000 and $471,000, which represented 9.5% and 10.1%, respectively, of our total operating expenses for those periods and $2.0 million and $2.7 million for the same periods in 2018, which represented 49.7% and 40.4%, respectively, of our total operating expenses for those periods.
Our ultimate success depends upon the outcome of a combination of factors, including: (i) successful commercialization of ContraPest and ongoing regulatory approvals of our other product candidates, (ii) market acceptance, commercial viability and profitability of ContraPest and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) our ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs.
Based upon our current operating plan, we expect that cash and cash equivalents at June 30, 2019, in combination with anticipated revenue, net proceeds of $3.6 million from the public offering completed on July 16, 2019 and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the next 12 months. However, if anticipated revenue targets and margin targets are not achieved and we are unable to raise necessary capital through the sale of our securities, we may seek to reduce operating expenses and take other measures that could impair our ability to be successful and operate as a going concern. In any event, we are likely to require additional capital in order to fund our operating losses and research and development activities until we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts.
Components of our Results of Operations
Net Sales
Net sales are comprised primarily of sales, net of discounts and promotions, of ContraPest and related components, to our distributors and customers.
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred in connection with the research and development of ContraPest and our other product candidates, which include:
- Employee related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
- Expenses incurred in connection with the development of our product candidates; and
Facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies.
We expense research and development costs as incurred.
We continue to investigate other applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates. At this time, we cannot reasonably estimate the costs for further development of ContraPest or the cost associated with the development of any of our other product candidates.
We plan to continue to hire employees to support our research and development efforts and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain employees for our research and development efforts. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our research and development expenses for the foreseeable future.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, sales, marketing and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.
We anticipate that our selling, general and administrative expenses may increase in the future as we increase our headcount to support commercialization of ContraPest and further development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.
We plan to continue to hire employees to support our commercialization of ContraPest and further development of our product candidates and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock- based compensation expense will continue to represent a significant portion of our selling, general and administrative expenses for the foreseeable future.
Interest Income
Interest income consists primarily of interest income earned on cash and cash equivalents.
Interest Expense
Interest expense consists primarily of interest accrued on our capital lease and note commitments.
Other Income (Expense), Net
Other income (expense), net, consists primarily of recognized change in value of short-term investments and income (expense) related to the year-over-year fair market value adjustment of our derivative warrant.
Income Taxes
Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate has been affected by the full valuation allowance on the Company’s deferred tax assets.
Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. At June 30, 2019, the Company has federal and state net operating loss carryforwards of approximately $52.3 million and $40.0 million, respectively, not considering any potential Internal Revenue Code of 1986 (“IRC”) Section 382 annual limitation discussed below. The federal loss carryforwards begin to expire in 2023, unless previously utilized. Approximately $7.9 million of those federal loss carryforwards, however, do not expire due to changes in U.S. tax law under the Tax Cuts and Jobs act of 2017. Additionally, the utilization of the net operating loss and tax credit carryforwards could be subject to an annual limitation under IRC sections 382 and 383, and similar state tax provisions due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by IRC Sections 382 and 383. results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period. The Company has not conducted an analysis of an ownership change under IRC Section 382. To the extent that a study is completed and an ownership change is deemed to occur, the Company’s ability to utilize its net operating losses could be limited.
Comparison of the Three and Six Months Ended June 30, 2019 and 2018
The following table summarizes our results of operations for the three and six months ended June 30, 2019 and 2018:
| Revenue: | For the Three Months Ended June 30, 2019 | 2018 | For the Six Months Ended June 30, 2019 | 2018 |
|---|---|---|---|---|
| Sales | $24 | $36 | $43 | $55 |
| Cost of sales | 21 | 20 | 33 | 39 |
| Gross profit (loss) | 3 | 16 | 10 | 16 |
| Operating expenses: | ||||
| Research and development | 463 | 636 | 927 | 1,270 |
| General and administrative | 1,831 | 3,465 | 3,735 | 5,493 |
| Total operating expenses | 2,294 | 4,101 | 4,662 | 6,763 |
| Net operating loss | (2,291) | (4,085) | (4,652) | (6,747) |
| Other income (expense): | ||||
| Interest income | 11 | 1 | 26 | 7 |
| Interest expense | (11) | (22) | (24) | (44) |
| Other income (expense) | 2 | (7) | (3) | 6 |
| Total other income (expense) | 2 | (28) | (1) | (31) |
| Net loss | $(2,289) | $(4,113) | $(4,653) | $(6,778) |
| Weighted average common shares outstanding - basic and fully diluted | 24,552,553 | 16,696,051 | 24,038,333 | 16,596,770 |
| Net loss per common share - basic and fully diluted | $(0.09) | $(0.25) | $(0.19) | $(0.41) |
Three Months Ended June 30, 2019 compared to Three Months Ended June 30, 2019:
Net Sales
Net sales were $24,000 for the three months ended June 30, 2019 and $36,000 for the same period in 2018. Sales were lower in 2019 due to the transition to the removal of ContraPest’s ‘restricted use only’ status at the state level, increased sales discounts to incentivize sales activity and the timing of a product exchange that was not re-shipped prior to the end of the quarter.
Cost of Sales
Cost of sales was $21,000 for the three months ended June 30, 2019, compared to $20,000 for the three months ended June 30, 2018. Cost of sales were slightly higher in 2019 due to an increase in scrap related to continued manufacturing scale up activities during the second quarter of 2019.
Gross Profit
Gross profit for the three months ended June 30, 2019 was $3,000 or 12.5% of net sales, compared to a gross profit of $16,000 or 44.4% of net sales, for the same period in 2018. The decrease in gross profit was a direct result of increased sales discounts and to incentivize sales and an increase in scrap due to related to scaleup activities.
Research and Development Expenses
(in thousands)
| Direct research and development expenses: Unallocated expenses: | Three Months Ended June 30, 2019 | 2018 | Increase (Decrease) |
|---|---|---|---|
| Personnel related (including stock-based compensation) | $245 | $344 | $(99) |
| Facility-related | 61 | 55 | 6 |
| Other | 157 | 237 | (80) |
| Total research and development expenses | $463 | $636 | $(173) |
Research and development expenses were $463,000 for the three months ended June 30, 2019, compared to $636,000 for the same period in 2018. The $173,000 decrease in research and development expenses was primarily due to a decrease of $99,000 in personnel-related costs, including stock-based compensation expense, due to the classification of certain field support employees to sales and marketing and option grants fully vesting resulting in lower expense. With more focus on commercialization of ContraPest, it was determined that these certain field support employees previously classified as research and development are now refocused on sales and marketing efforts and thus, reclassified as such.
Facility-related expense increased $6,000 due primarily to facility lease payment escalation.
The decrease in other research and development expenses of $80,000 was primarily due to a reclass of other expenses related to certain field support employees to sales and marketing as described above.
We continue to investigate other applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were approximately $1.8 million for the three months ended June 30, 2019, as compared to approximately $3.5 million for the three months ended June 30, 2018. The decrease of $1.7 million in selling, general and administrative expenses was primarily due to lower stock compensation expense of $1.7 million associated with inducement warrants issued in June 2018. In addition, increased travel expenses of approximately $17,000 due to the reclassification of certain field support employees was offset by lower professional services expenses due to decreased legal activity in the quarter ending June 30, 2019.
Interest Income/Expense, Net
We recorded interest income/expense of $0, net, for the three months ended June 30, 2019, as compared to interest expense, net of $21,000 for the same period in 2018. The $21,000 decrease in interest expense was a result of decreased interest on capital leases and promissory notes that were fully paid during the three months ended June 30, 2019 and higher interest income as a result of higher average daily cash balance and interest rates year over year.
Other Income (Expense)
We recorded $2,000 of other income, net, for the three months ended June 30, 2019, compared to $7,000 of other expense for the same period in 2018. The $9,000 net increase in other income was primarily due to decreased expense related to the year-over-year fair market value adjustment of our derivative warrant.
Six Months Ended June 30, 2019 compared to Six Months Ended June 30, 2019:
Net Sales
Net sales were $43,000 for the six months ended June 30, 2019 and $55,000 for the same period in 2018. Sales were lower in 2019 due to the transition to the removal of ContraPest’s ‘restricted use only’ status at the state level, increased sales discounts to incentivize sales activity and the timing of a product exchange that was not re-shipped prior to June 30, 2019.
Cost of Sales
Cost of sales was $33,000 for the six months ended June 30, 2019, compared to $39,000 for the six months ended June 30, 2018. Cost of sales were lower in 2019 primarily due to lower sales volume.
Gross Profit
Gross profit for the six months ended June 30, 2019 was $10,000 or 23.3% of net sales, compared to a gross profit of $16,000 or 29.1% of net sales, for the same period in 2018. The decrease in gross profit was a direct result increased sales discounts to incentivize sales activity.
Research and Development Expenses
(in thousands)
| Direct research and development expenses: Unallocated expenses: | Six Months Ended June 30, 2019 | 2018 | Increase (Decrease) |
|---|---|---|---|
| Personnel related (including stock-based compensation) | $462 | $759 | $(297) |
| Facility-related | 124 | 114 | 10 |
| Other | 341 | 397 | (56) |
| Total research and development expenses | $927 | $1,270 | $(343) |
Research and development expenses were $927,000 for the six months ended June 30, 2019, compared to $1.3 million for the same period in 2018. The $343,000 decrease in research and development expenses was primarily due to a decrease of $297,000 in personnel-related costs, including stock-based compensation expense, due to the classification of certain field support employees to sales and marketing. With more focus on commercialization of ContraPest, it was determined that these certain field support employees previously classified as research and development are now refocused on sales and marketing efforts and thus, reclassified as such.
Facility-related expense increased $10,000 due primarily to facility lease payment escalation.
The decrease in other research and development expenses of $56,000 was primarily due to a reclass of other expenses related to certain field support employees to sales and marketing as described above.
We continue to investigate other applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were approximately $3.7 million for the six months ended June 30, 2019, as compared to approximately $5.5 million for the six months ended June 30, 2018. The decrease of $1.8 million in selling, general and administrative expenses was primarily due to lower stock compensation expense of $1.7 million associated with inducement warrants issued in June 2018 and $500,000 due to option grants fully vesting resulting in lower stock compensation expense offset by increased salary and wages due to the reclassification of certain field support employees of $332,000 and an increase of $207,000 in professional services expense. The increase in professional services expenses was primarily due to increased legal and Board of Directors related expenses.
Interest Income/Expense, Net
We recorded interest income of $2,000, net, for the six months ended June 30, 2019, as compared to interest expense, net of $37,000 for the same period in 2018. The $39,000 increase in interest incomes was a result of decreased interest on capital leases and promissory notes that expired during the six months ended June 30, 2019 and higher interest income as a result of higher average daily cash balance and interest rates year over year.
Other Income (Expense)
We recorded $3,000 of other expense, net, for the six months ended June 30, 2019, compared to $6,000 of other income for the same period in 2018. The $9,000 net decrease in other income was primarily due to increased expense related to the year-over-year fair market value adjustment of our derivative warrant.
Liquidity and Capital Resources
Since our inception, we have sustained significant operating losses in the course of our research and development activities and commercialization efforts and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began full scale marketing of our first product, ContraPest, and we continue to develop other product candidates, which are in various phases of development. We have funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock; debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees. Through June 30, 2019, we had received net proceeds of $63.6 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.4 million in net product sales. At June 30, 2019, we had an accumulated deficit of $90.5 million and cash and cash equivalents of $2.6 million.
Our ultimate success depends upon the outcome of a combination of factors, including: (i) successful commercialization of ContraPest and ongoing regulatory approval of our other product candidates; (ii) market acceptance, commercial viability and profitability of ContraPest and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs.
Based upon our current operating plan, we expect that cash and cash equivalents at June 30, 2019, in combination with anticipated revenue, net proceeds of $3.6 million from the sale of 3,037,038 shares of the Company’s common stock at a price of $1.35 per share on July 16, 2019 and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the next 12 months. However, if anticipated revenue targets and margin targets are not achieved and we are unable to raise necessary capital through the sale of our securities, we may seek to reduce operating expenses and take other measures that could impair our ability to be successful and operate as a going concern. In any event, we are likely to require additional capital in order to fund our operating losses and research and development activities until we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts.
Additional Funding Requirements
We expect our expenses to increase in connection with our ongoing activities, particularly as we market and focus on sales of ContraPest, and as we advance field studies of our product candidates in development. In addition, we will continue to incur costs associated with operating as a public company.
In particular, we expect to incur substantial and increased expenses as we:
- Work to maximize market acceptance for, and generate sales of, our products;
- Manage the infrastructure for the sales, marketing and distribution of ContraPest and any other product candidates for which we may receive regulatory approval;
- Continue the development of ContraPest and our other product candidates, including engaging in any necessary field studies;
- Seek additional regulatory approvals for ContraPest and our other product candidates;
- Scale up manufacturing processes and quantities to meet future demand of ContraPest and any other product candidates for which we receive regulatory approval;
- Continue product development of ContraPest and advance our research and development activities and advance the research and development programs for other product candidates;
- Maintain, expand and protect our intellectual property portfolio; and
- Add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.
Based upon our current operating plan, we expect that cash and cash equivalents at June 30, 2019, in combination with anticipated revenue, net proceeds of $3.6 million from the public offering completed on July 16, 2019 and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the next 12 months. However, if anticipated revenue targets and margin targets are not achieved and we are unable to raise necessary capital through the sale of our securities, we may seek to reduce operating expenses and take other measures that could impair our ability to be successful and operate as a going concern. In any event, we are likely to require additional capital in order to fund our operating losses and research and development activities until we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts.
Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented:
| Six Months Ended June 30, 2019 | 2018 | |
|---|---|---|
| Cash used in operating activities | $(3,907) | $(4,553) |
| Cash provided by (used in) investing activities | (47) | 2,691 |
| Cash provided by financing activities | 1,609 | 1,608 |
| Net increase (decrease) in cash and cash equivalents | $(2,345) | $(254) |
Operating Activities.
During the six months ended June 30, 2019, operating activities used $3.9 million of cash, primarily resulting from our net loss of $4.7 million offset by changes in our operating assets and liabilities of $59,000 and by non-cash charges of $687,000, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash provided by changes in our operating assets and liabilities for the six months ended June 30, 2019 consisted primarily of a net increase in accrued expenses and accounts payable of $135,000, a decrease in prepaid expenses of $13,000 and a decrease in deposits of $4,000 offset by an increase in inventory of $70,000, an increase in receivables of $17,000 and a decrease in deferred rent of $6,000.
During the six months ended June 30, 2018, operating activities used $4.6 million of cash, primarily resulting from our net loss of $6.8 million and by changes in our operating assets and liabilities of $733,000, partially offset by non-cash charges of $3.0 million, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the six months ended June 30, 2018 consisted primarily of an increase in inventory of $648,000, prepaid expenses of $32,000, a decrease in accounts payable/accrued expenses of $27,000, an increase in receivables of $21,000 and a decrease in deferred rent, offset by a decrease in deposits of $7,000.
Investing Activities.
For the six months ended June 30, 2019, we used $47,000 in net cash related to investing activities due to purchases of property and equipment.
For the six months ended June 30, 2018, net cash of $2.7 million was provided by investing activities consisting of $2.6 million of proceeds received from the sale of securities held to maturity and $185,000 of proceeds from the sale of equipment offset by $102,000 in purchases of property and equipment.
Financing Activities.
During the six months ended June 30, 2019, net cash provided by financing activities was $1.6 million as a result of proceeds from the exercise of warrants of $1.8 million offset by payments of $112,000 related to notes payable, $38,000 in payments of capital lease obligations and $24,000 of payments for employee withholding taxes related to share-based awards.
During the six months ended June 30, 2018, net cash provided by financing activities was $1.6 million as a result of $2.2 million in proceeds from warrant exercises offset by payments of $335,000 of deferred offering costs, $207,000 of repayments of related to notes payable and notes payable, related party, $36,000 in repayments of capital lease obligations and $27,000 of payments for employee withholding taxes related to share-based awards.
Off-Balance Sheet Arrangements
None.
Critical Accounting Policies and Significant Judgments and Estimates
Our financial statements are prepared in accordance with U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.
There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the three months and six months ended June 30, 2019 and 2018, respectively.
Stock-Based Compensation
We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures, in accordance with ASC Topic 718 — *Stock Compensation (“*ASC 718”). We estimate the grant date fair value of the awards, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these stock options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The fair value of the stock options granted to non-employees is re-measured as the stock options vest and is recognized in the statements of operations and comprehensive loss during the period the related services are rendered.
We recorded stock-based compensation expense of approximately $219,000 and $471,000 for the three and six months ended June 30, 2019, respectively and $2.0 million and $2.7 million for the three and six months ended June 30, 2018, respectively. We expect to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.
The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and loss per share of common stock could have been significantly different. Our assumptions are as follows:
- Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
- Expected volatility. Expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.
- Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
- Expected dividend. The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
- Expected forfeitures. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.
Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock
As noted above, we are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. In the absence of an active market for our common stock, we utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of our common stock. In addition, we have conducted periodic assessments of the valuation of our common stock.
The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income and net income per share amounts could have been significantly different. The fair value per share of our common stock for purposes of determining stock-based compensation expense is the closing price of our common stock as reported on the applicable grant date. The compensation cost that has been included in the statements of operations and comprehensive loss for all stock-based compensation arrangements is as follows:
| Three Months Ended June 30, 2019 | 2018 | Six Months Ended June 30, 2019 | 2018 | |
|---|---|---|---|---|
| Research and development | $1 | $29 | $10 | $58 |
| General and administrative | 218 | 2,008 | 461 | 2,677 |
| Total stock-based compensation expense | $219 | $2,037 | $471 | $2,735 |
The intrinsic value of stock options outstanding as of June 30, 2019 was $0.
Emerging Growth Company Status
The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we intend to comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.
Controls and procedures
As filed, 1,574 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We conducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act), under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e)) as of the end of the period covered by this report.
These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to management, including the principal executive and principal financial officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2019, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 127 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in the risk factors set forth in Part I, Item 1A, “Risk Factors” in our 2018 Annual Report.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $24.0k | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $43.0k | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $21.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $33.0k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $3.0k | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $10.0k | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $463.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $927.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$4.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$2.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$4.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.09 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.19 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$3.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $47.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $2.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $4.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $5.4m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $1.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $1.5m | us-gaap:Liabilities |
| Long-term debt | At period end2019-06-30 | $196.0k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-06-30 | $134.0k | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2019-06-30 | $134.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2019-06-30 | $3.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-19-015650. Last ingested by Listed: Nov 14, 2026, 18:52 ET. Listed shows no prices and gives no investment advice.